Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10969081 | Vaccine | 2011 | 6 Pages |
Abstract
The active hospital-based surveillance showed a decline in the annual incidence rates of pneumococcal meningitis during the period of study, from 1.12 cases to 0.83 cases/100,000 persons for all age groups (P < 0.001), with an overall case-fatality rate of 28.6% (113 of 395) for all patients and 41.9% (57 of 136) for those <5 years of age. Serotypes 14 (n = 55; 13.9%), 3 (n = 32; 8.1%), 23F (n = 32; 8.1%), 19F (n = 31; 7.8%), 6B (n = 30; 7.6%), 18C (n = 28; 7.1%), and 6A (n = 20; 5%) were the most prevalent serotypes. In patients <5 years the estimated projected coverage of 7-, 10- and 13-valent conjugate vaccines was 74.3%, 75.7% and 83.1%, respectively. Antimicrobial susceptibility testing revealed that 22.1% (n = 88) of isolates were non-susceptible to penicillin, 56% were non-susceptible to trimethoprim/sulphamethoxazole, and 29.6% were non-susceptible to tetracycline. Nonsusceptibility to penicillin and cefotaxime was detected solely among serotype 14 isolates (n = 4; 1%). This study provides an important baseline to assess the impact of conjugate vaccine implantation on the epidemiology of meningitis due to Streptococcus pneumoniae in Salvador, Brazil.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ana Paula de O. Menezes, Leila C. Campos, Milena S. dos Santos, Jailton Azevedo, Renan C.N. dos Santos, Maria da Gloria S. Carvalho, Bernard W. Beall, Stacey W. Martin, Katia Salgado, Mitermayer G. Reis, Albert I. Ko, Joice N. Reis,